Home | homepage Sub Sub | VisionGate uses $2.6 million NIH grant to achieve full Automation of Cell-CT™ 3D imaging system for early diagnosis of cancer

VisionGate uses $2.6 million NIH grant to achieve full Automation of Cell-CT™ 3D imaging system for early diagnosis of cancer

VisionGate, Inc., a company developing a revolutionary non-invasive test for the early detection of lung cancer and other applications, today reported that it has achieved full automation of its Cell-CT™ system, a proprietary imaging platform that generates high-resolution 3D biosignatures from intact cells. Development of the fully automated system was funded in part by a $2.6 million grant from the National Institutes of Health’s (NIH) BRDG-SPAN program (Biomedical Research, Development, and Growth to Spur the Acceleration of New Technologies). Separately, VisionGate announced that it will be presenting at the OneMedForum 2012 Finance Conference in San Francisco on Tuesday, January 10, 2012.

More information : VG_NIH_Grant

VisionGate named winner of Arizona Governer's celebration of Innovation Award for start-up company innovator of the year

PR Newswire-Addresses Key Issue from Landmark NCI NLST Lung Cancer Study-How to Manage High Rate of False Positive Results

VisionGate named a finalist for the Governor's Celebration of Innovation

Frost & Sullivan – Medical and Diagnostic Imaging Technology Alert

Medical Device Daily – VisionGate presents at OneMedForum 2012 Conference

VisionGate uses $2.6 million NIH grant to achieve full Automation of Cell-CT™ 3D imaging system for early diagnosis of cancer

VisionGate named winner of Arizona Governer’s celebration of Innovation Award for start-up company innovator of the year

VisionGate closes $2 million financing and announces collaboration to evaluate it’s 3D Cell Imaging platform for early lung cancer detection

This website may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and made in reliance on the "safe harbor" provisions of said act. Forward-looking statements are based on estimates, projections, beliefs and assumptions of VisionGate management at the time of such statements and are not guarantees of future performance. Forward-looking statements involve risks and uncertainties in predicting future results and conditions. Actual results could differ materially from those projected in these forward-looking statements due to a variety of factors, including, without limitation, the acceptance by customers of our products, our ability to develop new products cost-effectively, our ability to raise capital in the future, the development by competitors of products using improved or alternative technology, the retention of key employees and general economic conditions. Forward-looking statements are subject to change without notice.

Copyright 2011 - Visiongate 3d